Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02658279 · ClinicalTrials.gov registry record · NA
Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
A NA study of Glioma and Recurrent Malignant Glioma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 27
- Enrollment target
- 16
- Study locations
NCT02658279: Active NA study of Glioma and Recurrent Malignant Glioma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02658279 is a NA study of Glioma and Recurrent Malignant Glioma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 27 participants, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (87% lower). The trial reports 16 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02658279, a NA study of Glioma and Recurrent Malignant Glioma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to test if the study drug called pembrolizumab could control the growth or shrink the cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by half, or prevent it from growing for at least 6 months. Pembrolizumab is an antibody that targets the immune system and activates it to stop cancer growth and/or kill cancer cells.
Primary Outcome
patients with stable disease will be considered responders if disease is stable for 27 weeks or more. The regimen will be considered worthy of further study if responses as defined above are observed in at least 3 of the 12 subjects. All subjects will undergo DCE-MRI of the head at the time points specified in Study Flow Chart . Local radiologic assessment of tumor measurements will be used during the study for clinical management and investigator-assessed disease progression. Additional MRIs ma
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (16)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
New Jersey
- Memorial Sloan Kettering Cancer Center - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
California
- University of California, Los Angeles - Los Angeles
- University of California San Francisco - San Francisco
Florida
- University of Miami - Miami
Ohio
- Cleveland Clinic - Cleveland
Texas
- Md Anderson Cancer Center - Houston
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2016-01-22 |
| Est. Completion | 2027-01 |
| Phase | NA |
What the registry record for NCT02658279 still lists
NCT02658279 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Glioma appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02658279 lists 16 locations in 8 states (New York, Massachusetts, New Jersey).
Frequently Asked Questions
What is clinical trial NCT02658279 about?
NCT02658279 is a clinical study titled "Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype". The purpose of this study is to test if the study drug called pembrolizumab could control the growth or shrink the cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by half, or prevent it from growing for at least 6 months. Pembrolizumab ...
What is the current status of trial NCT02658279?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 27 participants. The study started on 2016-01-22. Estimated completion is 2027-01.
What conditions does trial NCT02658279 study?
This clinical trial studies the following conditions: Glioma, Recurrent Malignant Glioma.
What interventions are being tested in trial NCT02658279?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02658279?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02658279 being conducted?
This trial has 16 study locations across California, Florida, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02658279's enrollment target sits among peer trials
27 62nd of 87 higher than 26 of 87 other Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tumor Treating Fields for the Treatment of Brainstem Gliomas
RECRUITING · NA
-
ASCENT Intervention for Brain Tumor Patients
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Recurrent Gliomas
RECRUITING · NA
-
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI